Anzeige
Mehr »
Mittwoch, 24.06.2026 - Börsentäglich über 12.000 News
Die 0,61-CAD-Uranaktie, die den Giganten hinterherjagt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
24.06.26 | 18:13
27,760 Euro
-2,08 % -0,590
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
27,54027,76020:45
27,66027,93020:45

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20:42Julie Kim Takes Helm as Takeda CEO1
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
12:48TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::2026 ANNUAL INTEGRATED REPORT1
12:47TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::TAKEDA ANNOUNCES NEW ASSIGNMENTS OF DIRECTORS AND APPOINTMENT OF NEW CEO1
12:42TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::NOTICE OF RESOLUTIONS AT THE 150TH ANNUAL GENERAL MEETING OF SHAREHOLDERS3
12:07TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer4
11:12Takeda Names Julie Kim CEO As Christophe Weber Retires357TOKYO (dpa-AFX) - Takeda Pharmaceutical Co. Ltd. (TAK, 4502.T) announced on Wednesday that it has appointed Julie Kim as President and CEO, completing an 18-month leadership transition.Former...
► Artikel lesen
09:54Takeda finalizes 18-month transition: Julie Kim officially appointed President & CEO18
09:42Takeda appoints Julie Kim as president and CEO8
09:34Takeda ernennt Julie Kim zur neuen President und CEO6
DiBeim Pharmakonzern Takeda wackeln rund 200 Jobs in Wien25
DiTakeda Canada Announces Positive Topline Results For Phase 3 LATITUDE Atlas Study For Psoriasis314OTTAWA (dpa-AFX) - Takeda Canada, Inc., a Canadian subsidiary of Japan's Takeda Pharmaceutical Co. Ltd. (TAK), announced Tuesday positive topline results for the Phase 3, randomized, multicenter...
► Artikel lesen
DiTakeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations4
17.06.Takeda's new study data for oveporexton shows improvements in narcolepsy type 111
17.06.TAKEDA PHARMACEUTICAL CO LTD - 20-F, Annual and transition report of foreign private issuers4
16.06.Takeda: Oveporexton Improves Daily Function, Cognition, Nighttime Sleep In Narcolepsy Type 1331TOKYO (dpa-AFX) - Takeda (TAK, 4502.T) presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton or TAK-861 improved daily functioning as well as cognitive and...
► Artikel lesen
11.06.Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med9
11.06.Takeda psoriasis drug tops Bristol-Myers Sotyktu in late-stage study10
11.06.Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest3
11.06.Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test10
11.06.Takeda's TYK2 inhibitor beats Bristol Myers' Sotyktu in phase 3 psoriasis showdown8
Weiter >>
172 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1